SCD-HeFT

Sudden Cardiac Death in Heart Failure Trial

Patient / Population Intervention / Exposure Comparison Outcome

In 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.

2,521

Design

RCT, double-blind drug arms

Endpoint

All-cause mortality

Relevance

ResultICD HR 0.77; amiodarone no better than placebo.

Bardy GH, et al. N Engl J Med. 2005;352(3):225-237. 10.1056/NEJMoa043399

Discussion & critique

Extended ICD benefit to non-ischaemic HF and showed amiodarone is not prognostically useful. The benefit was concentrated in NYHA class II.